Herbal composition phy906 and its use in chemotherapy

Patent metadata

Field	Value
Publication number	US-2020306331-A1
Application number	US-202016848233-A
Country	US
Kind code	A1
Filing date	Apr 14, 2020
Priority date	Feb 15, 2007
Publication date	Oct 1, 2020
Grant date	—

Abstract

This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy.

First claim

1 - 17 . (canceled)

18 . A composition for treating cancer in a mammal in need thereof comprising a therapeutically effective amount of an herbal preparation administering to the mammal in combination with sorafenib, wherein the herbal preparation comprises a therapeutically effective amount of Scutellaria, Glycyrrhiza, Ziziphus , and Paeonia ; and a therapeutically effective amount of sorafenib, said composition being formulated in pharmaceutical dosage form in combination with a pharmaceutically acceptable carrier, additive and/or excipient thereof.

19 . The composition according to claim 18 wherein said herbal preparation comprises Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba , and Paeonia lactiflora.

20 . The composition according to claim 18 wherein said cancer is hepatocellular cancer.

21 . The composition according to claim 19 wherein said cancer is hepatocellular cancer.

22 . The composition according to claim 18 wherein said cancer is colorectal cancer.

23 . The composition according to claim 19 wherein said cancer is colorectal cancer.

24 . The composition according to claim 18 wherein said cancer is pancreatic cancer.

25 . The composition according to claim 19 wherein said cancer is pancreatic cancer.

26 . The composition according to claim 18 which is in oral dosage form.

27 . The composition according to claim 18 which is in parenteral dosage form.

28 . The composition according to claim 18 , wherein the mammal is a human.

29 . The composition according to claim 19 , wherein the mammal is a human.

30 . The composition according to claim 20 , wherein the mammal is a human.

31 . The composition according to claim 21 , wherein the mammal is a human.

32 . A composition for use in inhibiting the growth of a tumor comprising
i) an anti-tumor effective amount of a herbal preparation comprising Scutellaria, Glycyrrhiza, Ziziphus , and Paeonia ; and ii) a chemotherapeutic formulation comprising an anti-tumor effective amount of sorafenib, in combination with a pharmaceutically acceptable carrier, additive and/or excepient wherein said tumor is a tumor of a gastrointestinal cancer.

33 . The composition according to claim 32 wherein said gastrointestinal cancer is hepatocellular cancer, colorectal cancer or pancreatic cancer.

34 . The composition according to claim 32 wherein said herbal preparation comprises Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba , and Paeonia lactiflora.

35 . The composition according to claim 33 wherein said cancer is hepatocellular cancer.

36 . The composition according to claim 34 wherein said cancer is hepatocellular cancer.

37 . The composition according to claim 33 wherein said cancer is colorectal cancer.

38 . The composition according to claim 34 wherein said cancer is colorectal cancer.

41 . The composition according to claim 34 wherein said cancer is pancreatic cancer.

42 . The composition according to claim 34 wherein said cancer is pancreatic cancer.

43 . The composition according to claim 32 in oral dosage form.

44 . The composition according to claim 32 in parenteral dosage form.

45 . The composition according to claim 32 , wherein the mammal is a human.

46 . The composition according to claim 33 , wherein the mammal is a human.

47 . The composition according to claim 34 , wherein the mammal is a human.

48 . The composition according to claim 35 , wherein the mammal is a human.

Assignees

• Univ Yale

Inventors

• Liu Shwu-Huey
• Jiang Zaoli
• Cheng Yung-Chi

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K36/725 Primary

  Ziziphus, e.g. jujube · CPC title

• A61K31/7068

  having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

• A61K36/539

  Scutellaria (skullcap) · CPC title

• A61K36/484

  Glycyrrhiza (licorice) · CPC title